Efficacy and safety of pegylated liposomal doxorubicin and epirubicin as neoadjuvant chemotherapy for breast cancer

AimThis study aims to compare the efficiencies and toxicities of pegylated liposomal doxorubicin (PLD) based and epirubicin based chemotherapeutic regimens as neoadjuvant chemotherapy (NAC) for early breast cancer.Patients and methodsWe retrospectively analyzed 391 patients with stage II-III breast...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Yuanyuan Shen, Qingling Hua, Menghao Dong, Wei Jin, Xueyang Hu, Kangsheng Gu
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Frontiers Media S.A. 2024-12-01
Edice:	Frontiers in Cell and Developmental Biology
Témata:	breast cancer neoadjuvant chemotherapy pegylated liposomal doxorubicin epirubicin efficacy
On-line přístup:	https://www.frontiersin.org/articles/10.3389/fcell.2024.1448037/full
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!